Drug Claim Symptoms Spread Among Supplement Marketers Targeting Ebola Fears
This article was originally published in The Tan Sheet
Executive Summary
The latest FDA/FTC joint warning letters advise Life Silver, Bodyhealth.com LLC and Ebola-C Inc. that their online claims render their products unapproved new drugs. FDA directs the firms to respond to an “EbolaTaskForce-CFSAN” email address rather than to an ORA address typical of most warning letters.
You may also be interested in...
Ebola Crisis Causes Drug Claim Symptoms In Products Marketed As Supplements
FTC joins FDA in one of the three warning letters to firms claiming their products can either prevent or treat Ebola. One firm’s website offers a video titled, “Urgent Message to Ebola-Stricken Nations' Heads of State,” and another claims “primary uses for oregano include athlete’s foot, candida, canker sores, Ebola virus.”
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.